Satake T, Morizane C, Rikitake R, et al. The epidemiology of rare types of hepatobiliary and pancreatic cancer from national cancer registry. J Gastroenterol. 2022;57:890–901.

Article  PubMed  PubMed Central  Google Scholar 

Ikezawa K, Urabe M, Kai Y, et al. Comprehensive review of pancreatic acinar cell carcinoma: epidemiology, diagnosis, molecular features and treatment. Jpn J Clin Oncol. 2024;54:271–81.

Article  PubMed  Google Scholar 

Wisnoski NC, Townsend CM Jr, Nealon WH, et al. 672 patients with acinar cell carcinoma of the pancreas: a population-based comparison to pancreatic adenocarcinoma. Surgery. 2008;144:141–8.

Article  PubMed  Google Scholar 

Huang X, Li M, Zhang L, et al. Clinical characteristics and treatment analysis of pancreatic acinar cell carcinoma: a single institutional comparison to pancreatic ductal adenocarcinoma. Surg Oncol. 2021;37: 101528.

Article  PubMed  Google Scholar 

Petrova E, Wellner J, Nording AK, et al. Survival outcome and prognostic factors for pancreatic acinar cell carcinoma: retrospective analysis from the German Cancer registry group. Cancers (Basel). 2021;13:6121.

Article  PubMed  Google Scholar 

Bellotti R, Paiella S, Primavesi F, et al. Treatment characteristics and outcomes of pure Acinar cell carcinoma of the pancreas—a multicentric European study on radically resected patients. HPB (Oxford). 2023;25:1411–9.

Article  PubMed  Google Scholar 

Shin SH, Hwang HK, Jang JY, et al. Clinical characteristics of resected acinar cell carcinoma of the pancreas: a Korean multi-institutional study. Cancers (Basel). 2021;13:5095.

Article  CAS  PubMed  Google Scholar 

Takahashi H, Ikeda M, Shiba S, et al. Multicenter retrospective analysis of chemotherapy for advanced pancreatic acinar cell carcinoma: potential efficacy of platinum- and irinotecan-containing regimens. Pancreas. 2021;50:77–82.

Article  PubMed  Google Scholar 

Xu JY, Guan WL, Lu SX, et al. Optimizing chemotherapy of pancreatic acinar cell carcinoma: our experiences and pooled analysis of literature. Clin Med Insights Oncol. 2022;16:11795549221090186.

Article  PubMed  PubMed Central  Google Scholar 

Stossel C, Raitses-Gurevich M, Atias D, et al. Spectrum of response to platinum and PARP inhibitors in germline BRCA-associated pancreatic cancer in the clinical and preclinical setting. Cancer Discov. 2023;13:1826–43.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Florou V, Elliott A, Bailey MH, et al. Comparative genomic analysis of pancreatic acinar cell carcinoma (PACC) and pancreatic ductal adenocarcinoma (PDAC) unveils new actionable genomic aberrations in PACC. Clin Cancer Res. 2023;29:3408–17.

Article  CAS  PubMed  Google Scholar 

Sakakida T, Ishikawa T, Doi T, et al. Genomic landscape and clinical features of rare subtypes of pancreatic cancer: analysis with the national database of Japan. J Gastroenterol. 2023;58:575–85.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kindler HL, Hammel P, Reni M, et al. Overall survival results from the POLO trial: a phase III study of active maintenance olaparib versus placebo for germline BRCA-mutated metastatic pancreatic cancer. J Clin Oncol. 2022;40:3929–39.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Golan T, Hammel P, Reni M, et al. Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer. N Engl J Med. 2019;381:317–27.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sakakida T, Ishikawa T, Doi T, et al. Genomic profile and clinical features of MSI-H and TMB-high pancreatic cancers: real-world data from C-CAT database. J Gastroenterol. 2023;59:145–56.

Article  PubMed  Google Scholar 

Umemoto K, Yamamoto H, Oikawa R, et al. The molecular landscape of pancreatobiliary cancers for novel targeted therapies from real-world genomic profiling. J Natl Cancer Inst. 2022;114:1279–86.

Article  PubMed  PubMed Central  Google Scholar 

Yamai T, Ikezawa K, Sugimoto N, et al. Utility of comprehensive genomic profiling tests for patients with incurable pancreatic cancer in clinical practice. Cancers (Basel). 2023;15:970.

Article  CAS  PubMed  Google Scholar 

Takahashi K, Takeda Y, Ono Y, et al. Current status of molecular diagnostic approaches using liquid biopsy. J Gastroenterol. 2023;58:834–47.

Article  PubMed  PubMed Central  Google Scholar 

Skorupan N, Ghabra S, Maldonado JA, et al. Two rare cancers of the exocrine pancreas: to treat or not to treat like ductal adenocarcinoma? J Cancer Metastasis Treat. 2023;9:5.

CAS  PubMed  PubMed Central  Google Scholar 

Mandelker D, Marra A, Zheng-Lin B, et al. Genomic profiling reveals germline predisposition and homologous recombination deficiency in pancreatic acinar cell carcinoma. J Clin Oncol. 2023;41:5151–62.

Article  CAS  PubMed  Google Scholar 

Nakayama S, Fukuda A, Kou T, et al. A case of unresectable ectopic acinar cell carcinoma developed in the portal vein in complete response to FOLFIRINOX therapy. Clin J Gastroenterol. 2023;16:610–4.

Article  PubMed  Google Scholar 

Izumo W, Higuchi R, Furukawa T, et al. A case of pathologically complete response after preoperative chemotherapy in a pancreatic acinar cell carcinoma patient with portal vein tumor thrombosis. Clin J Gastroenterol. 2022;15:642–8.

Article  PubMed  Google Scholar 

Okusaka T, Nakamura M, Yoshida M, et al. Clinical practice guidelines for pancreatic cancer 2022 from the Japan Pancreas Society: a synopsis. Int J Clin Oncol. 2023;28:493–511.

Article  PubMed  PubMed Central  Google Scholar 

Tempero MA, Malafa MP, Al-Hawary M, et al. Pancreatic adenocarcinoma. version 2.2021, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2021;19:439–57.

Article  CAS  PubMed  Google Scholar 

Pilié PG, Tang C, Mills GB, et al. State-of-the-art strategies for targeting the DNA damage response in cancer. Nat Rev Clin Oncol. 2019;16:81–104.

Article  PubMed  PubMed Central  Google Scholar 

Kim KH, Kim HS, Kim SS, et al. Increased radiosensitivity of solid tumors harboring ATM and BRCA1/2 mutations. Cancer Res Treat. 2022;54:54–64.

Article  PubMed  Google Scholar 

Price JM, Prabhakaran A, West CML. Predicting tumor radiosensitivity to deliver precision radiotherapy. Nat Rev Clin Oncol. 2023;20:83–98.

Article  CAS  PubMed  Google Scholar